Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

G1 Therapeutics Inc (GTHX-RM)

Moscow
Currency in RUB
Disclaimer
604.00
0.00(0.00%)
Real-time Data
Fair Value
Unlock Value
Day's Range
551.00661.00
52 wk Range
459.001,849.00
Bid/Ask
557.00 / 604.00
Prev. Close
600
Open
660
Day's Range
551-661
52 wk Range
459-1,849
Volume
0
Average Vol. (3m)
186
1-Year Change
0%
Shares Outstanding
52,199,394
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
8.50
Upside +90.16%

People Also Watch

2.62
ESPR
-2.96%
6.88
LUNR
-3.51%
5.75
SMR
+38.10%
5.750
CRDF
+6.68%
6.00
SOUN
+3.27%
How do you feel today about GTHX-RM?
Vote to see community's results!
or

G1 Therapeutics Inc Company Profile

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.